Nektar Therapeutics Stock Falls Despite Positive Alopecia Trial Data
Nektar Therapeutics shares declined 19% on Thursday, reaching $49.15, marking the largest percentage drop since February 24, 2023. This occurred despite the release of promising long-term trial data for the company's experimental alopecia areata treatment.